DMB-3115 showed similar efficacy and safety to ustekinumab in a phase 3 trial for plaque psoriasis, with comparable PASI score reductions. The study involved 598 patients, with no clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback